Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Meyvisch

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
American Journal of Respiratory and Critical Care Medicine|April 28, 2017
Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis RegimensAndreas H Diacon, Elana van Brakel, Nacer Lounis, et al.
Plos One|July 20, 2018
Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trialPaul Meyvisch, Chrispin Kambili, Koen Andries, et al.
Antiviral Therapy|October 26, 2011
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trialMichael Manns, Henk Reesink, Thomas Berg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patientsHans-Jürgen Stellbrink, Keikawus Arastéh, Dirk Schürmann, et al.
Advances in Therapy|October 1, 2019
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial DesignEva Santermans, Paul Ford, Michael Kreuter, et al.
Annals of the Rheumatic Diseases|April 17, 2026
Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)Isabelle Peene, Gwenny M Verstappen, Suzanne Arends, et al.
Gastroenterology|October 27, 2009
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patientsHenk W Reesink, Gregory C Fanning, Khalid Abou Farha, et al.
The European Respiratory Journal|December 10, 2015
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosisAlexander S Pym, Andreas H Diacon, Shen-Jie Tang, et al.
The New England Journal of Medicine|August 21, 2014
Multidrug-resistant tuberculosis and culture conversion with bedaquilineAndreas H Diacon, Alexander Pym, Martin P Grobusch, et al.
The New England Journal of Medicine|June 5, 2009
The diarylquinoline TMC207 for multidrug-resistant tuberculosisAndreas H Diacon, Alexander Pym, Martin Grobusch, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
American Journal of Respiratory and Critical Care Medicine|April 28, 2017
Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis RegimensAndreas H Diacon, Elana van Brakel, Nacer Lounis, et al.
Plos One|July 20, 2018
Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trialPaul Meyvisch, Chrispin Kambili, Koen Andries, et al.
Antiviral Therapy|October 26, 2011
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trialMichael Manns, Henk Reesink, Thomas Berg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patientsHans-Jürgen Stellbrink, Keikawus Arastéh, Dirk Schürmann, et al.
Advances in Therapy|October 1, 2019
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial DesignEva Santermans, Paul Ford, Michael Kreuter, et al.
Annals of the Rheumatic Diseases|April 17, 2026
Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)Isabelle Peene, Gwenny M Verstappen, Suzanne Arends, et al.
Gastroenterology|October 27, 2009
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patientsHenk W Reesink, Gregory C Fanning, Khalid Abou Farha, et al.
The European Respiratory Journal|December 10, 2015
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosisAlexander S Pym, Andreas H Diacon, Shen-Jie Tang, et al.
The New England Journal of Medicine|August 21, 2014
Multidrug-resistant tuberculosis and culture conversion with bedaquilineAndreas H Diacon, Alexander Pym, Martin P Grobusch, et al.
The New England Journal of Medicine|June 5, 2009
The diarylquinoline TMC207 for multidrug-resistant tuberculosisAndreas H Diacon, Alexander Pym, Martin Grobusch, et al.
Pageof 2